Results 81 to 90 of about 379,262 (266)

Gynecology and Obstetrics

Clinical and Applied Thrombosis/Hemostasis, 2013
A. Nicolaides, J. Fareed, A. K. Kakkar, A. J. Comerota, S. Z. Goldhaber, R. Hull, K. Myers, M. Samama, J. Fletcher, E. Kalodiki, D. Bergqvist, J. Bonnar, J. A. Caprini, C. Carter, J. Conard, B. Eklof, I. Elalamy, G. Gerotziafas, G. Geroulakos, A. Giannoukas, I. Greer, M. Griffin, S. Kakkos, M. R. Lassen, G. D. O. Lowe, A. Markel, P. Prandoni, G. Raskob, A. C. Spyropoulos, A. G. Turpie, J. M. Walenga, D. Warwick   +31 more
openaire   +2 more sources

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population‐Based Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pain and fever are common in pregnancy. Dipyrone is widely used in Europe, Latin America, and parts of Asia, but is banned in other countries due to concerns about agranulocytosis. Evidence on its safety in pregnancy remains limited and inconsistent. This study aimed to evaluate whether maternal dipyrone use during the first‐ and third‐trimesters is ...
Itamar Ben Shitrit, Daphna Idan, Ariel Avraham Hasidim, Tal Michael, Amalia Levy, Gali Pariente, Eitan Lunenfeld, Sharon Daniel   +7 more
wiley   +1 more source

Editorial: Editors' showcase: obstetrics and gynecology

Frontiers in Medicine, 2023
Simcha Yagel, Sarah M. Cohen
doaj   +1 more source

Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model‐Based Analysis of Mother–Infant Pairs for Tuberculosis Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
IMPAACT 2001 (NCT02651259) evaluated the safety and pharmacokinetics (PK) of once‐weekly isoniazid and rifapentine in pregnant and postpartum women for tuberculosis prevention. Rifapentine (RPT) and desacetyl rifapentine (desRPT) PK data were collected in maternal plasma, breast milk, infant cord blood, and infant plasma.
Priya Jayachandran, Jyoti S. Mathad, Nan Zhang, Paula Britto, Lubbe Wiesner, Grace Montepiedra, Jennifer Norman, Ellen Townley, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato, Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Amita Gupta, Kelly E. Dooley, Radojka Savic, on behalf of the IMPAACT 2001 Study Team   +18 more
wiley   +1 more source

Author’s Keywords Index

Gynecology Obstetrics & Reproductive Medicine, 2021
Gynecology Obstetrics and Reproductive Medicine
doaj  

Model‐Informed Dose Optimization of Anakinra in Preterm Neonates Implications for Safe and Effective Dosing

Clinical Pharmacology &Therapeutics, EarlyView.
Anakinra, an interleukin‐1 receptor antagonist, shows promise for reducing inflammatory complications of premature birth. However, the pharmacokinetics (PK) of anakinra in neonates has not been characterized, limiting evidence‐based dosing. This study aimed to develop a population PK model for anakinra to guide dosing in preterm neonates.
Jia Li, David K. Metz, Elys Green, Gergely Toldi, Robert Galinsky, Megan Clark, Rebecka Atkinson, Ina Rudloff, Josephine C. Owen, Sara K. DiSimone, Samuel C. Forster, Steven X. Cho, Atif Majid, Graeme R. Polglase, Marcel Favilla, Pramod Pharande, Atul Malhotra, Calum T. Roberts, Scott H. Stansfield, Arvind Sehgal, Kenneth Tan, Alistair J. Gunn, Philip J. Berger, Alex Veldman, Rod W. Hunt, Claudia A. Nold‐Petry, Marcel F. Nold, Carl M. J. Kirkpatrick   +27 more
wiley   +1 more source

Retracted: Intravenous Leiomyoma with Extension to the Heart: A Case Report and Review of the Literature

Case Reports in Obstetrics and Gynecology, 2014
Case Reports in Obstetrics and Gynecology
doaj   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Gynecologic and Obstetric Pathology [PDF]

Laboratory Investigation, 2016
openaire   +5 more sources